Clinical Trial Results:
A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have
Progressed on Anti-PD-1 Therapy
Summary
|
|
EudraCT number |
2019-000132-25 |
Trial protocol |
FR |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
28 Jul 2024
|
First version publication date |
28 Jul 2024
|
Other versions |
|
Summary report(s) |
ca224083-primary-csr-synopsis-redacted |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.